Document is current
Any future updates will be listed below
-
Authors
Bhowmik, Achol A. https://orcid.org/0000-0002-1491-5899
Heikkilä, Taina R. H.
Polari, Lauri https://orcid.org/0000-0002-0052-6489
Virta, Jenni https://orcid.org/0000-0003-1062-8187
Liljenbäck, Heidi https://orcid.org/0000-0001-9372-1584
Moisio, Olli https://orcid.org/0000-0002-2473-459X
Li, Xiang-Guo https://orcid.org/0000-0002-9118-7223
Viitanen, Riikka https://orcid.org/0000-0003-0937-356X
Jalkanen, Sirpa https://orcid.org/0000-0002-1922-9732
Koffert, Jukka https://orcid.org/0000-0003-3375-8961
Toivola, Diana M. https://orcid.org/0000-0001-7165-9839
Roivainen, Anne https://orcid.org/0000-0002-4006-7977
-
Funding
Funding for this research was provided by:
Terveyden Tutkimuksen Toimikunta (315139)
Terveyden Tutkimuksen Toimikunta (332582)
Terveyden Tutkimuksen Toimikunta (347251)
Terveyden Tutkimuksen Toimikunta (350117)
Sigrid Juséliuksen Säätiö
Jane ja Aatos Erkon Säätiö
Turun Yliopistollinen Keskussairaala (ERVA 13856)
Åbo Akademi
University of Turku
- License Information
-
More Information
Article History
Received: 29 September 2023
Revised: 1 December 2023
Accepted: 4 December 2023
First Online: 18 December 2023
Declarations
:
: SJ owns stocks in Faron Pharmaceuticals. The remaining authors have no competing interests to disclose.
: All animal experiments were approved by the national Project Authorization Board in Finland (licenses ESAVI/16359/2019 and ESAVI/8648/2020) and were carried out in compliance with the ARRIVE guidelines. Human intestinal samples were from patients with UC participating in a clinical trial approved by the joint Ethics Committee of the University of Turku and Turku University Hospital (CLN9801, ethics approval 31.3.1998 §76, and amendment CLN9901 16.3.1999 §97).
